Investor Presentaiton
Novo Nordisk Annual Report 2023
INNOVATION AND THERAPEUTIC FOCUS
Introducing Novo Nordisk Strategic Aspirations Risks
Broadening our pipeline for
long-term innovation
Management
Consolidated statements
Additional information
הויויו
23
23
As the world grapples with the
increasing impact of serious chronic
diseases, Novo Nordisk is amplifying
its research and development efforts
to tackle these global health
challenges head-on. Diseases like
diabetes, obesity, cardiovascular
disease and rare blood disorders
pose significant threats to human
health and society, demanding
urgent action.
Guided by our purpose to drive change to defeat serious chronic
diseases, we are broadening our pipeline of potential new
treatments with an approach that is as comprehensive as it is
innovative. Building on our 100-year heritage in protein and
peptide engineering, we are harnessing the power of novel
research technology platforms, leveraging cutting-edge data
science tools and forging new strategic partnerships. This
multi-faceted approach is enabling us to accelerate our research
efforts and expand our footprint across multiple disease areas.
As our evolution from a diabetes-focused organisation to a
broader cardiometabolic-focused company continues, our
attention remains on areas with the highest unmet needs - and
those where we are best positioned to compete. Strengthening
our leadership position in both diabetes and obesity remains
our top priority, while expanding our presence in cardiovascular
disease and rare blood disorders is also a key focus.
We are stepping up our investment in these areas to build and
maintain industry-leading pipelines, while at the same time
seeking new opportunities to complement our in-house
expertise with external innovation. Over the past year, this
emphasis on business development has resulted in the
acquisition of biotechs including Inversago Pharma and Embark,
two companies developing novel therapies with a potential
application across a range of cardiometabolic diseases.
To further expand our capabilities, we have established a
significant presence in the Greater Boston area, a world-
renowned hub for innovation and cutting-edge science and
technology. Through strategic partnerships, such as those
with technology firm Valo Health and the Broad Institute of
MIT and Harvard, we aim to accelerate our drug discovery and
development efforts, expanding our use of human data, artificial
intelligence and machine learning and tapping into our partners'
innovative genetics and genomics tools.
These extensive, wide-ranging efforts are already yielding
positive results, including the initiation of clinical testing for
cutting-edge cell therapy and siRNA (small interfering ribonucleic
acid) treatments. Armed with an increasing array of novel
research and development tools, we aim to move a greater
number of projects into clinical testing at a faster pace, reducing
the cost per project without compromising safety or quality.
STRATEGIC ASPIRATIONS 2025
1. Further raise the innovation-bar
for diabetes treatment
2. Develop a leading portfolio of superior
treatment solutions for obesity
3. Strengthen and progress the
Rare Disease pipeline
4. Establish presence in Cardiovascular
& Emerging Therapy Areas focusing
on CVD, MASH and CKDView entire presentation